ReviewTherapeutic advances in hematology2018
The evolution of stem-cell transplantation in multiple myeloma.
Review in Therapeutic advances in hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Allogeneic Stem Cell Transplantation for High/Ultra High-Risk Multiple Myeloma.Journal of hematology · 2025Article
- Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021.Annals of hematology · 2024Article
- The Efficacy and Safety of Tandem Transplant Versus Single Stem Cell Transplant for Multiple Myeloma Patients: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2024Review
- Review
- Current status of drug development for patients with multiple myeloma: a review of comparison in China and the rest of world.Antibody therapeutics · 2023Review
- Article
- Non-Cryopreserved Peripheral Blood Stem Cell Graft for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Lymphoma Patients.Annals of transplantation · 2023Article
- [Autologous stem cell transplantation improve the survival of newly diagnosed multiple myeloma patients].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Introduction to "Immunotherapies for Multiple Myeloma".Pharmaceuticals (Basel, Switzerland) · 2020Article
- Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma.Drugs · 2020Review
- Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.European journal of haematology · 2020Article
- Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.Clinical lymphoma, myeloma & leukemia · 2020Article
- Article
- Consensus recommendations for the role and competencies of the EBMT clinical pharmacist and clinical pharmacologist involved in hematopoietic stem cell transplantation.Bone marrow transplantation · 2020Review
- Immunotherapy for Multiple Myeloma.Cancers · 2019Review
- Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific Vβ T cell families.Journal for immunotherapy of cancer · 2019Article
- Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma.Bone marrow transplantation · 2019Article
- Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma.Drugs · 2019Review
- Autologous hematopoietic stem-cell transplant in small-sized and peripheral centers: a 10-year experiment.Therapeutic advances in hematology · 2019Article
- Autologous Stem Cell Transplantation in Multiple Myeloma with Renal Failure: Friend or Foe?Stem cells international · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous stem-cell transplantation (ASCT) remains an integral part of treatment for previously untreated, and may have value in the treatment of relapsed patients with, multiple myeloma (MM). The addition of novel agents like immunomodulators and proteasome inhibitors as induction therapy before and as consolidation/maintenance therapy after ASCT has led to an improvement in complete response (CR) rates, progression-free survival (PFS) and overall survival (OS). With advances in supportive care, older patients and patients with renal insufficiency are now able to safely undergo the procedure. The data concerning the timing of ASCT (early in the disease course or at first relapse), single
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.